Simon Spichak

Understand the impacts of how new AI tools are reshaping Canada’s benefits system on transparency and accountability for citizens.

Imaging suggests why the ability to make inferences declines after an episode of acute stress, such as a job interview. Imaging suggests why the ability to make inferences declines after an episode of acute stress, such as a job interview.

Despite the headlines, there’s limited evidence that using large language models – like Claude and ChatGPT – is rotting the brain. But there’s enough cause for concern.

A growing body of research suggests astrocytes, star-shaped brain cells once dismissed as support players, may lead the way to more precise and effective psychiatric drugs.

Calls by disability advocates and the UN to halt an expansion of medically assisted death have gone largely unacknowledged by the federal government

An analysis by The Sick Times find that less than 15% of Long COVID clinical trials testing the benefits of exercise or cardiopulmonary rehabilitation measured post-exertional malaise, according to their trial registration, while a handful excluded participants who experience it.

Though the NIH director is calling for $187 million more in funding for Alzheimer’s, the NIH is funding fewer new projects.

Charles Piller’s outlines claims that scientific fraud has blocked potential new discoveries to treating Alzheimer’s.

Guidelines recommend exercise and therapy as treatments, following attempted influence from Paul Garner.

Should healthy people take an Alzheimer’s biomarker blood test? Clinical guidelines say no. But Quest had a different idea.

As of May, 11 of the U.S.'s 35 Alzheimer's disease research centers no longer have federal funding. Teams are “scrambling” to continue their mission.